SGLT2 inhibitors improve global longitudinal strain in humans (4% improvement versus 2.2% with multiple daily injections; P<0.05).
“Hybrid closed-loop systems and SGLT-2i group displayed the most significant improvement in GLS (6.7 % and 4 %)”
Human trialPoorly controlled type 1 diabetes; SGLT-2i added to multiple daily injections versus intensified multiple daily injectionsmyocardium12 months
SGLT2 inhibitors are linked with better global longitudinal strain in humans (compared with control group not receiving SGLT2i) (ΔGLS -2.49% ± 0.54% vs -0.44% ± 0.52%).
“GLS improved significantly (ΔGLS: -2.49% ± 0.54% vs. -0.44% ± 0.52%, P < 0.001)”
Humanscompared with control group not receiving SGLT2iheart6 monthsn = 185
SGLT2 inhibitors are linked with better global longitudinal strain in humans (normal weight: -17.83 ± 1.30% to -19.22 ± 1.20%; overweight/obesity: -17.70 ± 1.48% to -19.05 ± 1.24%).
“Both groups showed significant GLS improvement (normal weight: -17.83 ± 1.30% to -19.22 ± 1.20%; overweight/obesity: -17.70 ± 1.48% to -19.05 ± 1.24%; both p < 0.001)”
Dapagliflozin is linked with lower global longitudinal strain in humans (Between-group difference -1.34 percentage points (95% CI -1.72 to -0.97); Cohen's d = 0.875).
“Compared with controls, dapagliflozin decreased GLS (between-group Δ: -1.34%, 95% CI: -1.72 to -0.97; Cohen's d = 0.875)”
Humansheart failure with preserved ejection fraction and chronic kidney disease; compared with conventional therapy without SGLT2iheart10 mg/day6 monthsn = 259
Hybrid closed-loop system improves global longitudinal strain in humans (Poorly controlled type 1 diabetes; compared with intensified multiple daily injections) (6.7% improvement versus 2.2% with multiple daily injections; P<0.05).
“Hybrid closed-loop systems and SGLT-2i group displayed the most significant improvement in GLS (6.7 % and 4 %)”
Human trialPoorly controlled type 1 diabetes; compared with intensified multiple daily injectionsmyocardium12 months
Insulin resistance is linked with lower global longitudinal strain in humans (Q4 vs. Q1) (MD -1.58 percentage points (95% CI: -2.22 to -0.93)).
“The random-effects pooled MD in GLS (Q4 vs. Q1) was -1.58 percentage points (95% CI: -2.22 to -0.93), indicating a lower strain magnitude (worse subclinical systolic function) in the highest IR group.”
Menopause was not clearly linked with global longitudinal strain in humans (menopausal versus perimenopausal women) (−19.62 ± 2.08% vs. −19.50 ± 1.96%; p = 0.723).
“GLS was similar in menopausal and perimenopausal women (−19.62 ± 2.08% vs. −19.50 ± 1.96%; p = 0.723)”
Humansmenopausal versus perimenopausal womenleft ventricular myocardiumfemalesn = 153
Mortality is associated with global longitudinal strain in humans (-19.2 ± 4.3 vs. -20.6 ± 3.5%).
“Subjects with adverse outcomes had significantly lower LV GLS (dead vs. alive; - 19.2 ± 4.3 vs. - 20.6 ± 3.5%, p < 0.05) and PALS (32.3 ± 12.0 vs. 41.8 ± 14.2%, p < 0.001)”
Global longitudinal strain is associated with incident heart failure in humans (Reduced GLS (>–16%); independent association beyond PREVENT) (HR 2.26 (95% CI 1.92–2.66)).
“Both markers were independently associated with HF: reduced GLS (>–16%) HR 2.26 (95% CI 1.92-2.66; p<0.001)”
Global longitudinal strain is associated with incident heart failure and cardiovascular death in humans (per 1% decrease in global longitudinal strain magnitude) (HR 1.16, 95% CI 1.02–1.31 per 1% decrease in GLS).
“a hazard ratio of 1.16 (95% CI 1.02-1.31) per 1% decrease in GLS for incident HF and cardiovascular death.”
Humansper 1% decrease in global longitudinal strain magnitudeheartn = 4,013
Global longitudinal strain predicts incident atrial fibrillation in humans (HR 1.13 per 1% decrease in GLS; 95% CI 1.01–1.27).
“After multivariable adjustment for clinical and echocardiographic parameters, the association remained significant in men (per 1% decrease: HR 1.13; 95% CI (1.01-1.27), p=0.038)”
HumansMultivariable-adjusted association; free of atrial fibrillation, heart failure, and prior stroke at baselineleft ventricleMedian follow-up of 5 yearsmales
Preeclampsia is associated with global longitudinal strain in humans (postpartum; previous preeclampsia compared with controls) (GLS MD 2.39 (95% CI 1.48 to 3.29); LVEF MD -2.76 (95% CI -4.61 to -0.90)).
“and also in women with PE (MD 2.39 [CI 95%: 1.48 to 3.29]; p<0.00001; I2 29% - Figure 1B).”
Reviewpostpartum; previous preeclampsia compared with controlsleft ventriclefemales
Hypertensive disorders of pregnancy is associated with global longitudinal strain in humans (postpartum; previous hypertensive disorders of pregnancy compared with controls) (GLS MD 1.23 (95% CI 0.60 to 1.85)).
“Postpartum GLS was significantly impaired in women with previous HDP compared with controls”
Reviewpostpartum; previous hypertensive disorders of pregnancy compared with controlsleft ventriclefemales
HIV infection is associated with global longitudinal strain in humans.
“HIV patients showed significantly lower values of global longitudinal strain of the left ventricle, right ventricle free wall and left atrial reservoir”
HumansLong-standing HIV infection without previous cardiovascular disease; compared with matched controlsleft ventricle, right ventricular free wall, and left atrial reservoir78.2% mensn = 110
Male rats with heart failure had heart relaxation times of 25.24 milliseconds with the inhibitor, compared with 27.20 milliseconds without it.Male rats with heart failure had heart relaxation times of 25.24 milliseconds with the inhibitor, compared with 27.20 milliseconds without it.
An observational analysis of 2,968 CARDIA participants and 4,294 MESA participants linked accumulated burden to unfavorable heart structure and function and higher…An observational analysis of 2,968 CARDIA participants and 4,294 MESA participants linked accumulated burden to unfavorable heart structure and function and higher cardiovascular event risk.